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ABSTRACT
  FK 506 is an immunosuppressive agent and highly stable 11-amino acid cyclic polypeptide. Present study demonstrated that FK 506 at the dose and 
time periods (1 mg / kg over 7 or 28 days impair the rat tissue based organic constituents, FK 506 depleted the rat tissue total protein, carbohydrate, lipid and 
glycogen contents of all rat tissues selected for the present study and whereas the same FK 506 treatment enhanced the rat tissues FAA and FFA contents: compared 
to saline treated rat control tissues. The overall data it is evident that FK 506 administration in the present study impairs the overall general metabolism of rat 
tissues. 
Keywords:  FK 506, Albino rat, Biomolecules. 
 
INTRODUCTION 
In the life on an organism, study of major organic constituents 
like proteins, lipids and their related metabolites provide the 
basis  for  an  understanding  of  overall  metabolism  of  the 
organism,  under  varied  environmental  pathological 
conditions. The organisms, however, they are known to orient 
their  overall  metabolism  to  overcome  their  own 
environmental  /  pathological  stress.  Proteins  have  been 
defined  as  extremely  complex  nitrogen  containing  organic 
compounds  which  are  found  in  all  animal  and  vegetable 
cells,  where  they  constitute  a  major  part  of  the  living 
protoplasm  of  these  cells.  The  proteins  differ  from 
carbohydrates and fats, not only in their function but also in 
their  elementary  composition.  Carbohydrates  compose  a 
large number of relatively heterogeneous compounds; these 
are  especially  prominent  constituents  of  plants.  A  fact 
primarily  attributable  to  the  abundance  of  cellulose  and 
starch,  but  also  occur  and  serve  important  functions  in 
animals.  These  serve  as the  chief  source  of  energy  in the 
food  of  humans  and  many  other  animals,  glucose  and 
glycogen  are  the  two  free  carbohydrate  compounds  of 
general utility in mammals. The other carbohydrate materials 
are, the pentoses, galactose, mannose, the aminosugars, the 
sugar  derived  organic  acids.  These  almost  exclusively  in 
mammals exist as constituent groups of complex molecules, 
such  as  compound  proteins  or  compound  lipids,  closely 
related to glucose and glycogen i.e., readily derived from 
them and convertible into them, are lactic acid and pyruvic 
acid.  The  term  lipids  is  applied  to  a  group  of  naturally 
occurring  substances  characterized  by  their  insolubility  in 
water and are soluble in fat solvents like ether, chloroform, 
benzene etc. Chemically, the lipids are either esters of fatty 
acids  or  substances  capable  of  forming  such  esters.  The 
oxidation of fats leads to the formation of fatty acids and  
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these  actively  participate  in  energy-generating  processes. 
The  main  storage  of  fat  is  the  adipose  tissue. 
Immunosuppressive agents such as FK 506 are well known to 
interact with membranes of cellular systems in experimental 
models. FK 506 is a neutral macrolide isolated from a soil 
fungus, Streptomyces tsukubaensis. FK 506 is 10 to 100 times 
more  potent  than  CsA  and  appears  to  affect  the  same 
common  early pathway as CsA1.    FK  506 is an  effective 
immunosuppressive  agent  in  liver,  pancreas,  kidney,  heart 
and  small  bowel  transplantation2.  Primarily  these  agents 
form  lipid  peroxides,  impair  glucose  tolerance  and  also 
interact with proteinaceous parts of cellular systems3. In view 
of this, the author at the outset studied the impact of FK 506 
on rat tissue major organic constituents.  
MATERIALS AND METHODS: 
Collection and growing Animals  
Albino  rats  weighing  150   10gm  were  selected  for  the 
present study. Animals were Fed ad libitum with commercial 
rat diet supplied by Kamadhenu Agencies, Bangalore, India 
and were housed at constant room temperature of 15  5oC. 
They were allowed to acclimate to laboratory conditions for 
at  least  ten  days  after  arrival  before  use.  Prior  to 
experiment, they were fasted for 24 hr with free access to 
water. They were divided into 4 groups of 7 each.  
Treatment of FK 506 with Rats: 
Group  I  &  II  rats  acted  as  controls,  received  only  saline 
(Oral) over 7 or 28 days respectively (daily doses). Group III 
rats were gavaged daily with 1 mg/kg body wt. of FK 506 
in 0.5ml of saline / 7 days, (short term) and group IV were 
gavaged daily with 1 mg / kg body wt. of FK 506 in 0.5ml 
of saline over 28 days (long term).  After 7 or 28 days of FK 
506  treatment  of  rats,  they  were  anaesthetized  with 
pentobarbitone  5  mg  /  kg  and  were  sacrificed.  Major 
tissues,  like  brain,  heart,  liver  and  kidney,  were  isolated, 
quickly  blotted  on  a  filter  paper,  weight  frozen  in  liquid 
nitrogen and were stored at -800C till used.  
Estimation of Total Proteins  
Total protein were estimated by the method of Lowry et al., 
(1951)4 using crystalline bovine serum albumin as standard. 
The  control  and  experimental  rat  tissues  were individually 
homogenized  (1%w/v)  in  distilled  water.  To  1.0ml  of  the 
homogenate, 2.0ml of 10% TCA was added to precipitate 
the proteins and the contents were centrifuged at 2000 xg 
for 15 min. The residue was dissolved in 1.0 ml 1N NaOH. 
To  0.1ml  of  this,  4.0  ml  of  alkaline  copper  reagent  was 
added followed by 0.4 ml of folin phenol reagent (1:1 folin 
phenol: water). The colour that developed was read at 600 
nm  in  a  spectrophotometer  against  a  reagent  blank.  The 
protein content was expressed as mg/g wet weight of tissue. 
Estimation of total carbohydrates 
Total  carbohydrate  content in  control and  FK-506  treated 
rat  tissues  was  estimated  by  the  method  of  Carrol et  al., 
(1956)5. The tissues were individually homogenized in 10% 
TCA and centrifuged at 3000 rpm for 15 minutes. To 1.0 ml 
of TCA supernatant 4.0 ml of anthrone reagent was added 
and the colour was read against a reagent blank at 600 nm 
in a spectrophotometer.  From the  optical  density,  the total 
carbohydrate content was calculated and compared with the 
standard. The values were expressed as mg of carbohydrate 
gm wet wt. of tissue.  
Estimation of total lipids 
The tissue total lipid content was estimated by the method of 
Folchh  et  al.,(1957)6  and  as  modified  by  Christie,  et  al., 
(1982)7. The individual tissues from control and experimental 
groups  were  homogenized  in  a  mixture  of  chloroform: 
methanol (2:1) and centrifuged at 3000 rpm for 15 minutes. 
A small quantity of water was added to the supernatant and 
the contents were vigorously shaken. The aquatic layer was 
separated from biphasic solution. A small aluminum boat was 
weighed and a known volume of the chloroform layer was 
added and evaporated at 50°- 60°C in a vacuum drying 
oven.  The  container  was  weighed  after  complete 
evaporation  of  the  chloroform  phase.  The  differences 
between initial and final weights gave the total lipid content. 
The lipid content was expressed as mg of total lipid / gm 
dry wt. of tissue.  
Estimation of free Amino Acids (FAA)  
The  total  FAA  content  in  control  and  FK  506  treated  rat 
tissues  was  estimated  by  the  method  of  Moore  and  Stein 
(1954)8.  Individual  tissue  was  homogenized  (3%)  and 
prepared  in  10%  TCA  and  centrifuged  at  600xg  for  15 
minutes.  To  0.2  ml  of  the  supernatant,  2ml  of  ninhydrin 
reagent  was  added  and was  kept in  boiling  water  for  6 
minutes and cooled immediately, at room temperature. The 
samples were made up to 10 ml with distilled water and the  
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colour was read at 575 nm in a spectrophotometer and the 
values  were  expressed  as  µM  of  tyrosine  /  g  wet  wt  of 
tissue.   
Estimation of free fatty Acids (FFA) 
In  the  control  and  experimental  tissues are  extracted  with 
chloroform:  methanol  mixture  (2:1)  ratio  and  FFA  present 
were  determined  by  suitably  modifying  the  procedure  of 
Schmidt  et  al.,  (1974)9  as  given  by  Bergmeyer  et  al., 
(1974)10.  The  samples  were  treated  with  chloroform  and 
copper reagent and the contents were thoroughly shaken for 
20  min.  Finally  the  chloroform  phase  was  carefully 
separated  with  the  help  of  a  separator  funnel.  The 
chloroform  phase  so  collected  was  taken  and  0.2  ml  of 
sodium diethyl dithiocarbanate was added to develop the 
colour.  The  colour  was  read  at  440nm  against  a  reagent 
blank. Stearic acid was used as standard. The values of FFA 
were expressed as µM of stearic acid/gm wet wt. of tissue. 
Estimation of Glycogen content  
Glycogen  content  in  control  and  experimental  tissues  was 
estimated  by  the  method  of  Carrol  et  al.,  (1956)5  using 
anthrone  reagent. Homogenates  5%  (w/v)  of tissues  were 
prepared  in  10%  trichloroacetic  acid.  The  homogenates 
were centrifuged for 10 minutes and the supernatant were 
taken for the estimation of glycogen. To known aliquots of 
supernatant,  5ml  of  95%  ethanol  was  added  and  the 
contents were kept in the refrigerator overnight for complete 
precipitation of glycogen. The contents were centrifuged for 
15 min at 1500 rpm and the residue was dissolved in 2ml of 
distilled water. To this, 4 ml of anthrone reagent was added 
and kept for 15 min. in boiling water bath. After cooling, the 
colour  was  measured  at  620nm  in  a  spectrophotometer 
against  a  reagent  blank.  The  blank received  1ml  of  10% 
trichloroacetic acid in the place of homogenate. The amount 
of glycogen is expressed in terms of mg glycogen/gm wet 
wt.  of tissue.  
Statistical Analysis  
For each parameter, the mean of individual observations (for 
both  control  and  experimental  groups)  were  taken  into 
consideration  statistical  significance  of  the  data  was 
analyzed through one way ANOVA.  
RESULTS  
The data presented in Table 1,2 and Fig 1 & 2 depicts that 
FK 506 at a dose of 1mg / kg in both short (7 days) and 
long term (28 days) treated rats decreased the rat brain, 
heart,  liver  and  kidneys  total  protein  content  and  the 
changes were found to be statistically significant (p < 0.01) 
for most of the tissues over the control. The decrease in the 
total protein content in FK 506 treated rat tissues was found 
to  be  time-dependent.  The  percent  depletion  of  FK  506 
treated rat tissue proteins was greater for the long term (28 
days) FK  506 treated  group  of tissues  compared  to  short 
term  (7  days)  FK  506  treated  ones,  and  the  percent 
depletion  was  more for liver  (51.20%)  followed  by heart 
(46.34%) > kidney (35.83%) and for brain (29.08%) (Table 
2 & Fig 2). Identical trends were also obtained for FK 506 
treated  rat  tissues  carbohydrates,  lipids  and  glycogen 
contents (Table 1, 2 and Fig.3-8). 
The FAA and FFA of FK 506 treated rat brain, heart, liver 
and  kidney like  tissues  showed  elevated  trends  over  their 
corresponding control values and the changes were found to 
be statistically significant (p < 0.01) (Table-1, Fig.9-12). The 
changes were found to be in a time and dose dependent 
manner.   
DISCUSSION  
FK  506  is  available  for  oral  administration  as  capsules 
(Tacrolimus  capsules)  containing  the  equivalent  of  0.5 
mg/1mg  or  5  mg  of  anhydrous  capsules.  Letko  et  al., 
(2001)11, have suggested a dose 1 mg or 5 mg for clinical 
trials. Inamura et al., (2004)12 have preferred an FK 506 
dose of 0.32mg/kg in rats. Nicoleth; have chosen an FK 506 
dose of 2.5 kg over 27 to 120 days in their experimental 
studies on rats. Kawashima et al., (1990)13 preferred an FK 
506 dose of 0.1 or 1 mg/ kg in their studies in rats as cited 
by Kahan et al., (1991)14 various authors have preferred 
0.5 mg/kg/day or 1mg/kg or 2 mg/kg over 1 or 2 weeks 
in their experimental studies. Thus multi center FK 506 liver 
study group (1994) preferred a dose of 0.5-2 mg of FK 506 
in their experiments. From the above it is evident that various 
authors have selected varied doses of FK 506. To study the 
toxic  effects  of  FK  506  in  their  experimental  models.  The 
author  of  the  present  study  has  conveniently  selected 
1mgkg/wt  of  FK  506 to  examine its in  vivo  effect  on  rat 
tissue oxidative metabolic parameters in the tissues of albino 
rats and the time periods selected were 7 days as short term 
and  28  days  as  long  term.  Decrease  in  rat  tissue  total 
protein  was  observed in  FK  506 treated  rat tissues  in the 
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Table 1: Effect of FK 506 on 7 days rat brain, heart, liver and kidney Total proteins (mg/g wet et), Total carbohydrate (mg/g wet wt), Total lipid (mg/g wet wt), Glycogen (mg/g wet wt), 
Free amino acids (mg/g wet wt) and Free Fatty acid (µM stearic acid/g wet wt) levels in vivo. 
Name of the Metabolite  
7 days  (1mg FK 506/kg wt) 
Brain  Heart  Liver  Kidney 
Control  Expt.  Control  Expt.  Control  Expt.  Control  Expt. 
Proteins  Av±SD 
PC 
77.30 + 1.58  62.00 + 1.80 
-19.79%* 
72.16 + 1.33  55.74 + 1.32 
-22.75%* 
88.69 +1.3  59.14 +0.642 
-33.31%* 
105.85 +1.20  84.14 +0.541 
-20.51%* 
Carbohydrates Av±SD 
PC 
36.53 + 0.306  25.96 + 0.224 
-28.93%* 
39.09 + 0.405  28.47 + 0.360 
-27.16%* 
57.69 + 0.964  34.94 + 0.361 
-39.43%* 
38.06 + 0.422  24.07 + 0.221 
-36.75%* 
Lipids       Av±SD 
PC 
292.67+ 2.93  266.09+ 1.96 
-9.08%*   
267.62 2.84  248.35 1.67 
-7.20* 
506.32 4.72  434.78 6.73 
-14.12* 
451.67 3.64  321.91 5.66 
-28.72* 
Glycogen     Av±SD 
PC 
2.86 0.210  2.32 0.096 
-18.88%* 
2.43 0.315 
 
 
2.07 0.083 
-14.81* 
12.32 0.424  6.76 0.364 
-45.12* 
2.60 0.032 
 
 
2.04 0.154 
-27.18%* 
Free amino acids Av±SD 
PC 
70.26 1.32 
 
79.06 0.961 
12.52% 
 
62.99 0.842  79.77 1.031 
26.63%* 
77.76 0.914  92.46 2.63 
18.90%* 
56.99 0.882  73.55 1.34 
29.05* 
Free fatty acids Av±SD 
PC 
241.56 3.69  253.08 2.16 
4.76%* 
161.08 1.72  173.67 2.49 
7.81%* 
170.42 1.37  181.27 2.08 
6.36%* 
105.18 1.94  157.79 2.64 
50.01%* 
 
Table 2: Effect of FK 506 on 28 days rat brain, heart, liver and kidney Total proteins (mg/g wet et), Total carbohydrate (mg/g wet wt), Total lipid (mg/g wet wt), Glycogen (mg/g wet wt), 
Free amino acids (mg/g wet wt) and Free Fatty acid (µM stearic acid/g wet wt) levels in vivo. 
Name of the Metabolite  
28 days (1mg FK 506/kg wt) 
Brain  Heart  Liver  Kidney 
Control  Expt  Control  Expt.  Control  Expt.  Control  Expt. 
Proteins  Av±SD 
PC 
78.01 +0.624  55.32+0.536 
-29.08%* 
75.00+1.05  40.24+0.436 
-46.34%* 
90.17+1.39  44.00+0.365 
-51.20%* 
105.91+1.47  67.96+0.522 
-35.83%* 
Carbohydrates Av±SD 
PC 
38.22+ 0.942 
 
20.18+ 0.761 
-47.20%* 
42.32+ 1.23  23.61+ 0.647 
-44.21%* 
59.19+ 1.08  22.06+ 1.149 
-62.73%* 
34.42+0.442  18.31+ 0.699 
-46.80%* 
Lipids       Av±SD 
PC 
293.11  1.36  252.24 3.22 
-16.20%* 
270.34 1.04  232.08 2.91 
-14.15%* 
510.36 4.30  305.94 2.16 
-40.05%* 
460.30 4.19  241.20 3.942 
-47.59%* 
Glycogen     Av±SD 
PC 
2.92 0.136 
 
2.06 0.022 
-29.45%* 
2.45 0.044  1.91 0.052 
-22.04* 
11.96 0.36  5.12 0.27 
-57.19%* 
2.63 0.036  1.73 0.046 
-34.22%* 
Free amino acids Av±SD 
PC 
74.24 1.26  83.14 2.041 
11.98%* 
63.340.96  87.22 0.74 
37.70%* 
79.31 1.36  105.23 2.491 
32.68%* 
57.23 0.78  82.35 0.88 
43.89%* 
Free fatty acids Av±SD 
PC 
243.41 2.41 
 
 
262.08 3.04 
7.67%* 
160.11 0.982  253.08 2.16 
58.06* 
174.32 1.23  193.05 2.37 
10.74* 
139.67 1.02  163.242.64 
16.87* 
Each value is the mean SD of 7 samples. AV: Average  SD: Standard Deviation   PC: percent change over control   Expt: Experimental p<0.01   
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Fig. 1: Effect of FK 506 on rat tissue Total Protein content in vivo
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Fig. 2: Effect of FK 506 on rat tissue Total Protein content in vivo
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Fig. 3: Effect of FK 506 on rat tissue Total Carbohydrate content in vivo
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Fig. 4: Effect of FK 506 on rat tissue Total Carbohydrate content in vivo
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Fig. 5: Effect of FK 506 on rat tissue Total Lipid content in vivo
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Fig. 6: Effect of FK 506 on rat tissue Total Lipid content in vivo
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Fig. 7: Effect of FK 506 on rat tissue Glycogen content in vivo
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Fig. 8: Effect of FK 506 on rat tissue Glycogen content in vivo
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Fig. 9: Effect of FK 506 on rat tissue Total Free Aminoacid levels in vivo
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Fig. 10: Effect of FK 506 on rat tissue Free Aminoacid levels in vivo
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Fig. 11: Effect of FK 506 on rat tissue Free Fatty acids levels in vivo
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Fig. 12: Effect of FK 506 on rat tissue Total Free Fatty acids levels in vivo
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present  study.  This  could  have  been  affected  through  an 
indirect stimulation of proteolytic activity which in turn could 
step up the rat tissues proteolytic activity in different tissues 
of the FK 506 treated rats causing lysis and break down of 
proteins.  Arise  in  proteolytic  activity  could  lead  to  the 
breakdown of proteins into their constituent amino acids and  
thinking at be responsible for elevated levels  of FAA in short 
and long term FK 506 treated rat tissues (Table 1 & 2). The 
pool of  FAA in  an organ represents  the  reservoir which is 
utilized  for  protein  synthesis  and  to  which  the  products  of 
protein degradation are returned. The increased FAA pools 
in FK 506 treated rat tissues may actively participate in the 
tricarboxylic  acid  cycle  to  generate  more  energy  to 
overcome the FK 506 induced toxic stress which is a common 
feature  in  most  of  the  animals  under  varied  stress 
conditions15. These results are in agreement with reports of 
the  earlier  author  from  our  laboratory,  where  for  an 
immunosuppressive agent like CsA at an administered dose 
of  10mg/kg  over  7  or  28  days  deplete  rat  tissues  total 
protein  content  and  enhance  the  level  of  rat  tissues  FAA 
content.  However,  the  author  could  not  find  any  citations 
related to FK 506 interaction of rat tissues total protein & 
FAA contents excepting to the available reports that FK 506 
do  interfere  with  calcineurin  –  linked  proteins  in  various 
experimental models (citations were made in the preceeding 
pages). CsA or FK 506 as soon as they are administered is 
accumulated  by  most  cells  in  the  body  and  at  high 
intracellular concentration they are cytotoxic16. Number of 
investigators  has  contributed  for  the  understanding  of  the 
mechanism  of  action  of  CsA  or  FK  506  most  of  their 
experimental studies involves T-cell mediated mechanisms. It 
appears that less  attention  was  paid to  understand  the in 
vivo effect of FK 506 on various basic organic constituents in 
experimental models. Hence, the author initially attempted to 
understand the fate of total proteins, carbohydrates, lipids, 
glycogen,  FAA  and  FFA  in  short  and  long  term  FK  506 
treated rat tissues.  
Concerning the results of total carbohydrate and glycogen 
levels in the control and FK 506 rat tissues in this study (table 
1,2 fig.2 & 3, 7 & 8), a drop in rat tissue total carbohydrate 
and glycogen contents was observed and the changes were 
found  to  be  statistically  significant  over  the  control  (p  < 
0.01).  Under  normal  metabolic  conditions,  carbohydrate 
utilization leads to enhanced levels of glycogen at least in 
tissues like liver. Glycogen, is the storage polysaccharide of 
the body and a major source of energy for the metabolic 
machinery.  Proper  maintenance  of  glycogen  reserves  for 
energy  is  one  of  the  important  features  of  normal 
metabolism.  In  the  present  study,  glycogen  content  was 
decreased in all the major tissues of  
FK 506 treated rats (Table 1 & 2). The balance between the 
demands for supply of energy in the form of glycogen seems 
to get disturbed upon FK 506 treatment. Corresponding to 
the decrease in tissue glycogen content, an elevation in serum 
glucose levels was previously reported by various authors17-
20.  Gluconeogenesis  is  the  breakdown  of  glycogen  into 
glucose  as  a  main  end  product  there  by  decreasing  the 
glycogen  content21.  FK  506  induced  glycogenolysis  may 
lead to hyperglycemia and, in addition a decrease in total 
carbohydrate content (Table 1 & 2) may be responsible for 
the  reported  changes  in  serum  glucose  content  in 
immunosuppressive  agents  like  FK  506  treated  animals20 
and the results of the present study are in agreement with 
the findings of the earlier authors20. The foregoing confirms 
that FK 506 treatment may induce a state of hyperglycemia 
and  glycogenolysis in  rat tissues  and these findings are in 
agreement  with  the  earlier  reports  17-20.  Studies  were 
further carried out to know the fate of total lipids and FFA 
like lipid metabolic profiles in control and FK 506 treated rat 
tissues in the present study. FK 506 treated rat brain, heart, 
liver  and  kidney  tissues  exhibited  lowered  levels  of  their 
total lipid content and elevated levels of their FFA content 
over their control group of tissues. The changes were more 
pronounced  for  rats  treated  with  FK  506  over  28  days 
compared to 7 days FK 506 treated group of rats (Table 1 
& 2). The decrease in the FK 506 treated rat tissue lipids 
could  either  be  due  to  increased  lypolysis  or  due  to  a 
reduction in the fatty acid synthesizing enzymes22. Curiously, 
the FFA increased in all the FK 506 treated rat tissues and 
this suggests an increased lypolysis. From the data obtained 
out of the present study, it is evident that FK 506 at the dose 
and time periods tested may induce a pathological condition 
like lipolysis. These alterations of FK-506 treated rat tissue 
total lipid and FFA might further be due to cell disruption of 
intracellular organelles due to FK 506 stress. Some support is 
available  regarding  this  hypothesis  from  the  reports  of  
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earlier authors23-25.  Lipid particles from damaged cells or 
organs  may  diffuse  more  rapidly  from  than  normal.  As  a 
result,  there  may  be  a  decrease  in  tissue  total lipids.  The 
elevated FFA with FK 506 might also be due to increased 
lytic activity of the lipase on triglycerides which releases FFA 
from parent substances, such as triglycerides, phospholipids, 
etc. (Bhattacharya and Maity, 1988, Ramani, 2002). From 
the overall data presented in table 1, it can be concluded 
that FK 506 by disrupting the overall organic constituents of 
rat tissue may impair the overall normal metabolism of the 
rat  tissues,  and  this  in  part  may  cause  neurotoxicity, 
myocardial toxicity, hepatotoxicity and nephrotoxicity in rat 
tissues.    
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